利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.028 秒)

    Method for Cloning T Cell Receptor
    14.
    发明申请
    Method for Cloning T Cell Receptor 审中-公开
    克隆T细胞受体的方法

    公开(公告)号：US20150203886A1

    公开(公告)日：2015-07-23

    申请号：US14417049

    申请日：2013-07-24

    申请人： National University Corporation University of Toyama

    发明人： Hiroyuki Kishi ,  Atsushi Muraguchi ,  Eiji Kobayashi ,  Tatsuhiko Ozawa

    IPC分类号： C12P19/34 ,  C12N15/85

    CPC分类号： C12P19/34 ,  C07K14/7051 ,  C12N5/0636 ,  C12N15/85

    摘要： An object is to provide a TCR closing system that enables not only bias-free analysis of TCR repertoires, but also collection of antigen-specific TCR α/β cDNA pairs and evaluation of functions thereof. There is provided a method for producing a gene of T cell receptor (TCR) specific to an antigen A, which comprises 1) the step of stimulating a group of T cells including a T cell specific to an antigen A or one T cell specific to an antigen A under a condition effective for amplification of a TCR gene; 2) the step of identifying a T cell specific to an antigen A among the group of T cells including a T cell specific to the antigen A, and sorting one T cell specific to the antigen A into a vessel; and 3) the step of subjecting the one activated T cell specific to the antigen A in the vessel to PCR to amplify a gene of TCR specific to the antigen A. According to the present invention, a target TCR gene can be cloned within a shorter time compared with that repaired by the conventional methods, for example, about ten days. Further, according to the present invention, genes of TCR α chain and β chain can be highly efficiently cloned. Under the conditions of the examples, a pair of a TCR α chain and TCR β chain could be obtained from stimulated T cells sorted as single cells at a ratio of 100%.

    摘要翻译： 目的是提供一种TCR闭合系统，其不仅能够对TCR谱系进行无偏差分析，而且可以收集抗原特异性TCRα/ bgr; cDNA对及其功能评价。 提供了一种用于产生对抗原A特异性的T细胞受体（TCR）的基因的方法，其包括：1）刺激一组T细胞的步骤，所述T细胞包括对抗原A特异的T细胞或一种特异于T细胞的T细胞 在有效扩增TCR基因的条件下的抗原A; 2）鉴定包含对抗原A特异性的T细胞的T细胞群中特异于抗原A的T细胞的步骤，将对抗原A特异性的1个T细胞分选成容器; 和3）将所述特异性的所述一种活化的T细胞对所述血管中的抗原A进行PCR以扩增针对所述抗原A特异性的TCR基因的步骤。根据本发明，靶TCR基因可以在较短的 时间与通过常规方法修理的时间相比，例如约十天。 此外，根据本发明，TCRα链的基因和 链可被高效克隆。 在实施例的条件下，一对TCRα链和TCR＆bgr; 链可以从以100％的比例分选为单细胞的刺激的T细胞获得。

    THREE-DIMENSIONAL GUIDE FOR WIRE FOR FORMING PEDICLE SCREW INSERTION HOLE AND METHOD OF PRODUCING THE SAME
    15.
    发明申请
    THREE-DIMENSIONAL GUIDE FOR WIRE FOR FORMING PEDICLE SCREW INSERTION HOLE AND METHOD OF PRODUCING THE SAME 审中-公开
    用于形成螺丝钉插入孔的线的三维指南及其生产方法

    公开(公告)号：US20130145812A1

    公开(公告)日：2013-06-13

    申请号：US13764048

    申请日：2013-02-11

    申请人： National University Corporation University of Toyama

    发明人： Yoshiharu KAWAGUCHI

    IPC分类号： B21F1/00

    CPC分类号： B21F1/00 ,  A61B17/1703 ,  A61B17/1757

    摘要： A three-dimensional guide for a wire for forming a pedicle screw insertion hole is produced based on a CT image of a spine, and includes a contact surface section that comes in surface contact with a morphological surface of a bone at an insertion site, and a guide block section that is provided upright from the contact surface section. The guide block section has a guide hole that restricts the insertion direction of the wire. The guide hole has an inner diameter slightly larger than the outer diameter of the wire. The guide hole has a length of 15 to 30 mm to restrict the insertion position and the insertion direction of the wire.

    摘要翻译： 基于脊柱的CT图像制造用于形成椎弓根螺钉插入孔的线的三维引导件，并且包括与插入部位的骨的形态表面接触的接触面部，以及 从接触表面部分直立设置的引导块部分。 引导块部具有限制线的插入方向的引导孔。 引导孔的内径略大于导线的外径。 引导孔的长度为15〜30mm，以限制线的插入位置和插入方向。

    WOUND CONTACT MEMBER
    18.
    发明公开
    WOUND CONTACT MEMBER 审中-公开

    公开(公告)号：US20230293766A1

    公开(公告)日：2023-09-21

    申请号：US18017209

    申请日：2020-10-22

    申请人： National University Corporation University of Toyama ,  SAKURA SEIKI CO., LTD.

    发明人： Kouji AMANO ,  Toshiko YOSHIDA ,  Motonori OKABE ,  Chika SOKO ,  Masahiko ARAKAWA

    IPC分类号： A61L27/36 ,  A61L27/60

    CPC分类号： A61L27/3604 ,  A61L27/3687 ,  A61L27/60

    摘要： The present invention addresses the problem of providing a wound contact member (or “contact layer”) that directly promotes wound healing when continuously performing negative pressure wound therapy (NPWT). As a solution, there is provided dry amniotic membrane manufactured by a specified drying process, that is, raw amniotic membrane placed inside a processing tank (10) is continuously heated using an infrared heater (14) provided inside the processing tank (10) while performing a depressurization operation that places the processing tank in a depressurized state and irradiation of the raw amniotic membrane with microwaves from a microwave generating device (30) provided inside the processing tank (10) to apply energy to water molecules present inside the amniotic membrane and cause drying during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank (10) toward atmospheric pressure. Amniotic membrane, which has been dried by repeating the above process and thereby retains its cell and tissue structure, is used as a contact layer when performing negative pressure wound therapy (NPWT) on an open abdominal wound and/or wound dehiscence, which increases the healing effect of NPWT.

    Magnesium alloy and magnesium alloy member
    20.
    发明授权
    Magnesium alloy and magnesium alloy member 有权

    公开(公告)号：US11268173B2

    公开(公告)日：2022-03-08

    申请号：US16763791

    申请日：2018-11-15

    申请人： Sumitomo Electric Industries, Ltd. ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA

    发明人： Manabu Mizutani ,  Katsuhito Yoshida ,  Seiji Saikawa

    IPC分类号： C22C23/02 ,  C22F1/06

    摘要： A magnesium alloy containing Al, Sr, Ca, and Mn, with the balance being Mg and inevitable impurities, the magnesium alloy having: a structure having an α-Mg phase, and a precipitate dispersed in at least one of a grain boundary of the α-Mg phase and a cell boundary, the precipitate including: at least one phase selected from a group A consisting of an Al2Sr phase, an Al4Sr phase, a (Mg, Al)2Sr phase, and a (Mg, Al)4Sr phase; and at least one phase selected from a group B consisting of an Al2Ca phase and a (Mg, Al)2Ca phase, the magnesium alloy having, in a cross section, a total area rate of a group A precipitate and a group B precipitate of greater than or equal to 2.5% and less than or equal to 30%.